Isis VP-Corporate Development Kate Winkler Corcoran: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Corcoran discusses firm’s strategy to license and develop specific targets developed through Isis’ proprietary RNA antisense technology.
Corcoran discusses firm’s strategy to license and develop specific targets developed through Isis’ proprietary RNA antisense technology.